AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30699314 — intervention group
Group type: COMPARATOR
Intervention: Single internal-thoracic-artery grafting
Number of subjects: 3102
Study 30526923 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA group)
Number of subjects: 70
Study 30526923 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid (spinal) anesthesia (S group)
Number of subjects: 70
Study 26477027 — intervention group
Group type: EXPERIMENTAL
Intervention: Strictly Monitored Exercise Programs (SMEP)
Number of subjects: 60
Study 26477027 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Program (UCP)
Number of subjects: 60
Study 23426563 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping treatment for gastrocnemius muscle enhancement and ankle functional correction
Number of subjects: 120
Study 23426563 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group for simulated Kinesio taping
Number of subjects: 120
Study 22323240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea
Number of subjects: 28
Study 22323240 — intervention group
Group type: COMPARATOR
Intervention: Soybean meal
Number of subjects: 28
Study 22323240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea and faba bean
Number of subjects: 28
Study 22323240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (all sources)
Number of subjects: 28
Study 20664017 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic insulin order template
Number of subjects: 128
Study 20664017 — intervention group
Group type: COMPARATOR
Intervention: Usual insulin ordering
Number of subjects: 128
Study 18246990 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (200 mg of caffeine)
Number of subjects: 24
Study 18246990 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping (30 minutes)
Number of subjects: 24
Study 18246990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee, 15 mg of caffeine)
Number of subjects: 24
Study 18246990 — intervention group
Group type: EXPERIMENTAL
Intervention: Napping
Number of subjects: 24
Study 18246990 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 24
Study 15883636 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg/day
Number of subjects: 1637
Study 15883636 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg/day
Number of subjects: 1637
Study 15883636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study 12393621 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 328
Study 12393621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 328
Study 12393621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (iron)
Number of subjects: 328
Study 12393621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sulfadoxine-pyrimethamine)
Number of subjects: 328
Study 12393621 — intervention group
Group type: EXPERIMENTAL
Intervention: Current or recent malarial infection
Number of subjects: 328
Study 12393621 — intervention group
Group type: EXPERIMENTAL
Intervention: Disappearance of malarial antigenemia
Number of subjects: 328
Study 11515632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 2 mg iv (group A)
Number of subjects: 54
Study 11515632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 54
Study 11515632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (group A)
Number of subjects: 54
Study 9016467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 12
Study 1642477 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 220
Study 1642477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 220
Study 1642477 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 220
Study 1642477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study 6388048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorad
Number of subjects: 42
Study 6388048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6388048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorad (in carcinoma uteri)
Number of subjects: 42
Study 31336290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warnings
Number of subjects: 870
Study 31336290 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warnings
Number of subjects: 870
Study 31336290 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warnings with quitline
Number of subjects: 870
Study 29264937 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided antibiotic treatment
Number of subjects: 0
Study 29264937 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 28389137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar protein shake (believed to be healthy)
Number of subjects: 0
Study 28389137 — intervention group
Group type: COMPARATOR
Intervention: Low-sugar protein shake
Number of subjects: 0
Study 28389137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar protein shake (labeled as healthy)
Number of subjects: 0
Study 28389137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar protein shake (labeled as indulgent)
Number of subjects: 0
Study 26220089 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic group therapy
Number of subjects: 199
Study 26220089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 199
Study 26220089 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 199
Study 24200220 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton SBRT (50Gy in 4 fractions)
Number of subjects: 10
Study 24200220 — intervention group
Group type: COMPARATOR
Intervention: Photon SBRT (50Gy in 4 fractions)
Number of subjects: 10
Study 21427564 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1.5 mg/kg body weight/d
Number of subjects: 15
Study 21427564 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 15
Study 18799092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 834
Study 18799092 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg once daily
Number of subjects: 834
Study 18799092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study 16434136 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (PSA testing every 4 years)
Number of subjects: 42176
Study 16434136 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 42176
Study 16434136 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 42176
Study 16434136 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 42176
Study 14655198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg plus 7 sevelamer hydrochloride 403 mg capsules (Arm B)
Number of subjects: 15
Study 14655198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg plus 4 calcium acetate 667 mg tablets (Arm C)
Number of subjects: 15
Study 14655198 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 750 mg alone (Arm A)
Number of subjects: 15
Study 11247403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C concentration
Number of subjects: 72
Study 11247403 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipapain activity
Number of subjects: 72
Study 11247403 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitrypsin activity
Number of subjects: 72
Study 11247403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C concentration in patients with microangiopathy
Number of subjects: 72
Study 11247403 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipapain and antitrypsin activities
Number of subjects: 72
Study 9262430 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca chewing (15 g of coca leaves)
Number of subjects: 16
Study 9262430 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free chewing gum (Coca‐ trial)
Number of subjects: 16
Study 8268557 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line automated method for measurement of dialyzer electrolyte clearance
Number of subjects: 0
Study 8268557 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive electrolyte clearance data
Number of subjects: 0
Study 8268557 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms for calculating delivered Kt/V
Number of subjects: 0
Study 3101386 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 10 micrograms X kg‐1
Number of subjects: 52
Study 3101386 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 20 micrograms X kg‐1
Number of subjects: 52
Study 3101386 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 30 micrograms X kg‐1
Number of subjects: 52
Study 3101386 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 40 micrograms X kg‐1
Number of subjects: 52
Study 30144513 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LBP and time‐integrated concentration (TIC) of LBP over 12 and 18 months
Number of subjects: 431
Study 30144513 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sTLR4 and TIC over 18 months
Number of subjects: 431
Study 27105047 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day (moderate intensity)
Number of subjects: 21
Study 27105047 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 60 mg/day (high intensity)
Number of subjects: 21
Study 24952726 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal cholecystectomy (TVC)
Number of subjects: 40
Study 24952726 — intervention group
Group type: COMPARATOR
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 40
Study 22438430 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 3687
Study 22438430 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents
Number of subjects: 3687
Study 22438430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 3687
Study 20805210 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.4% tetrahydrocannabinol
Number of subjects: 23
Study 20805210 — intervention group
Group type: COMPARATOR
Intervention: 0% tetrahydrocannabinol
Number of subjects: 23
Study 18054471 — intervention group
Group type: EXPERIMENTAL
Intervention: CHHiP IMRT planning
Number of subjects: 16
Study 18054471 — intervention group
Group type: COMPARATOR
Intervention: RT-01 planning
Number of subjects: 16
Study 17021791 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy (group 1)
Number of subjects: 216
Study 17021791 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-total thyroidectomy (group 2)
Number of subjects: 216
Study 12929292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 100
Study 10910027 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption using dextran sulfate (DS)‐cellulose columns
Number of subjects: 19
Study 10910027 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (mean dose 38 mg/day)
Number of subjects: 19
Study 8843769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous loxiglumide
Number of subjects: 8
Study 8843769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7938670 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic processing
Number of subjects: 0
Study 7938670 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-semantic processing
Number of subjects: 0
Study 7938670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued completion
Number of subjects: 0
Study 7938670 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncued completion
Number of subjects: 0
Study 7938670 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition
Number of subjects: 0
Study 3258993 — intervention group
Group type: EXPERIMENTAL
Intervention: co-trimoxazole (160 mg trimethoprim plus 800 mg sulphamethoxazole) every 12 hours for 15 days
Number of subjects: 50
Study 3258993 — intervention group
Group type: COMPARATOR
Intervention: cephalexin (500 mg) every 6 hours for 15 days
Number of subjects: 50
Study 29857271 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT (clopidogrel + aspirin)
Number of subjects: 44
Study 29857271 — intervention group
Group type: COMPARATOR
Intervention: SAPT (clopidogrel + placebo)
Number of subjects: 44
Study 29857271 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 44
Study 29857271 — intervention group
Group type: COMPARATOR
Intervention: SAPT
Number of subjects: 44
Study 29857271 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT and SAPT
Number of subjects: 44
Study 28258922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 82
Study 28258922 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 82
Study 27261980 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-bathing therapy at 40°C for 30 minutes daily for four weeks
Number of subjects: 30
Study 27261980 — intervention group
Group type: COMPARATOR
Intervention: Foot-bathing therapy at 36.5°C for 30 minutes daily for four weeks (placebo)
Number of subjects: 30
Study 27261980 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 23670066 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaSilk body and tights (group A)
Number of subjects: 22
Study 23670066 — intervention group
Group type: COMPARATOR
Intervention: Cotton clothes (group B)
Number of subjects: 22
Study 21057977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 or 500 mg twice daily)
Number of subjects: 44
Study 21057977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20084975 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A and C conjugate Vaccine with MenB‐OMP
Number of subjects: 458
Study 20084975 — intervention group
Group type: COMPARATOR
Intervention: Control group (other vaccine)
Number of subjects: 458
Study 17454586 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (e.g. melphalan, thalidomide)
Number of subjects: 0
Study 17454586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment with stem-cell support (autologous and allogeneic)
Number of subjects: 0
Study 15258016 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 45
Study 15258016 — intervention group
Group type: COMPARATOR
Intervention: Viscocanalostomy
Number of subjects: 45
Study 11529350 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 42
Study 11529350 — intervention group
Group type: COMPARATOR
Intervention: Non-obese children
Number of subjects: 42
Study 11529350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 9764894 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 285
Study 9764894 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of care (CMC)
Number of subjects: 285
Study 8567448 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural noise (65 dB SPL) presented for 408 ms before the click train.
Number of subjects: 7
Study 8567448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral noise (65 dB SPL) presented for 408 ms before the click train.
Number of subjects: 7
Study 8567448 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral noise (65 dB SPL) presented for 408 ms before the click train.
Number of subjects: 7
Study 8567448 — intervention group
Group type: COMPARATOR
Intervention: Without noise condition (baseline).
Number of subjects: 7
Study 2375668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic positional biofeedback (BFB)
Number of subjects: 37
Study 2375668 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) biofeedback
Number of subjects: 37
Study 2375668 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 37
Study 282700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin (POR 8)
Number of subjects: 0
Study 282700 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline
Number of subjects: 0
Study 31074328 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-directed reading of The Cat in the Hat
Number of subjects: 0
Study 31074328 — intervention group
Group type: COMPARATOR
Intervention: Control model parameters (lower lexical frequency, capitalization, first mention, likelihood of a syntactic boundary)
Number of subjects: 0
Study 31685285 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + AE (treatment as usual + aerobic exercises)
Number of subjects: 31
Study 31685285 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 31
Study 28627134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 159
Study 26293657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy group intervention (n=9)
Number of subjects: 19
Study 26293657 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (n=10)
Number of subjects: 19
Study 24068776 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 700
Study 24068776 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 700
Study 21420283 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 18
Study 21420283 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 18
Study 18803888 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac sodium
Number of subjects: 70
Study 18803888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16480566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural psychotherapy (CBT)
Number of subjects: 123
Study 12871871 — intervention group
Group type: COMPARATOR
Intervention: Metformin (2.55 g/day) for 12 months
Number of subjects: 13
Study 12871871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day) + Metformin diet for 10 months
Number of subjects: 13
Study 12871871 — intervention group
Group type: COMPARATOR
Intervention: Metformin diet for 26 responders (N=26)
Number of subjects: 13
Study 10965008 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation plus physical therapy
Number of subjects: 54
Study 10965008 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 54
Study 10965008 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (only in patients who underwent implantation)
Number of subjects: 54
Study 10965008 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 54
Study 1840440 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 0
Study 1840440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7233297 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE) 4 mg administered as an intrarectal suppository
Number of subjects: 0
Study 7233297 — intervention group
Group type: COMPARATOR
Intervention: Intravaginally administered PGE
Number of subjects: 0
Study 30849931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity physical activity (20, 2-minute breaks)
Number of subjects: 30
Study 30849931 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (20, 2-minute breaks)
Number of subjects: 30
Study 30849931 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical activity (20, 2-minute breaks)
Number of subjects: 30
Study 30849931 — intervention group
Group type: COMPARATOR
Intervention: Sedentary screen-time breaks
Number of subjects: 30
Study 29116326 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Radius (SR) implant
Number of subjects: 60
Study 29116326 — intervention group
Group type: COMPARATOR
Intervention: Multi-Radius (J-Curve, JC) implant
Number of subjects: 60
Study 27697868 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced video intervention
Number of subjects: 1170
Study 27697868 — intervention group
Group type: COMPARATOR
Intervention: Social marketing video intervention
Number of subjects: 1170
Study 24368003 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy intervention
Number of subjects: 124
Study 24368003 — intervention group
Group type: COMPARATOR
Intervention: Health promotion group intervention
Number of subjects: 124
Study 21875892 — intervention group
Group type: EXPERIMENTAL
Intervention: CCFES
Number of subjects: 21
Study 21875892 — intervention group
Group type: COMPARATOR
Intervention: Cyclic NMES
Number of subjects: 21
Study 20501479 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide (4 mg/1.25 mg)
Number of subjects: 10640
Study 20501479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10640
Study 17954317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 61
Study 17954317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 61
Study 17954317 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 61
Study 15735183 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with insulin aspart
Number of subjects: 100
Study 15735183 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy with insulin aspart and insulin glargine
Number of subjects: 100
Study 12521407 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 567
Study 12521407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 10435117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre, carbohydrate-rich breakfast
Number of subjects: 14
Study 10435117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fibre, carbohydrate-rich breakfast
Number of subjects: 14
Study 10435117 — intervention group
Group type: COMPARATOR
Intervention: Fat-rich breakfasts
Number of subjects: 14